Oxford Immunotec Global (NASDAQ:OXFD) Stock Rating Lowered by BidaskClub
OXFD has been the subject of several other research reports. Zacks Investment Research cut Oxford Immunotec Global from a buy rating to a hold rating in a research note on Thursday, August 1st. TheStreet cut Oxford Immunotec Global from a c- rating to a d+ rating in a research note on Monday, July 15th. Finally, ValuEngine cut Oxford Immunotec Global from a hold rating to a sell rating in a research note on Wednesday, September 4th. Two equities research analysts have rated the stock with a sell rating, one has assigned a hold rating and one has assigned a buy rating to the stock. The stock has a consensus rating of Hold and a consensus target price of $18.00.
NASDAQ:OXFD traded up $0.18 during trading hours on Tuesday, reaching $13.83. 592 shares of the company traded hands, compared to its average volume of 97,235. Oxford Immunotec Global has a 1 year low of $11.88 and a 1 year high of $19.19. The business’s 50-day moving average price is $13.46 and its two-hundred day moving average price is $14.93. The company has a current ratio of 13.35, a quick ratio of 12.76 and a debt-to-equity ratio of 0.03. The stock has a market capitalization of $364.09 million, a P/E ratio of 27.01 and a beta of 0.37.
In other Oxford Immunotec Global news, CEO Peter Wrighton-Smith sold 10,000 shares of the business’s stock in a transaction dated Friday, August 16th. The stock was sold at an average price of $13.86, for a total transaction of $138,600.00. Following the completion of the sale, the chief executive officer now owns 424,538 shares of the company’s stock, valued at $5,884,096.68. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director Richard A. Sandberg sold 3,000 shares of the business’s stock in a transaction dated Thursday, August 1st. The shares were sold at an average price of $19.90, for a total value of $59,700.00. The disclosure for this sale can be found here. Insiders own 4.21% of the company’s stock.
Several hedge funds and other institutional investors have recently added to or reduced their stakes in OXFD. Tower Research Capital LLC TRC boosted its stake in shares of Oxford Immunotec Global by 34.9% in the second quarter. Tower Research Capital LLC TRC now owns 2,734 shares of the company’s stock worth $37,000 after acquiring an additional 708 shares during the period. Aperio Group LLC bought a new position in shares of Oxford Immunotec Global in the second quarter worth about $42,000. BNP Paribas Arbitrage SA boosted its stake in shares of Oxford Immunotec Global by 59,988.9% in the first quarter. BNP Paribas Arbitrage SA now owns 5,408 shares of the company’s stock worth $93,000 after acquiring an additional 5,399 shares during the period. C M Bidwell & Associates Ltd. bought a new position in shares of Oxford Immunotec Global in the second quarter worth about $93,000. Finally, Susquehanna International Group LLP bought a new position in shares of Oxford Immunotec Global in the second quarter worth about $162,000. 94.09% of the stock is owned by hedge funds and other institutional investors.
About Oxford Immunotec Global
Oxford Immunotec Global PLC, a diagnostics company, focuses on developing and commercializing proprietary tests for immunology and infectious diseases in the United States. It develops its products using its T-SPOT technology platform, which enables the measurement of responses of specific immune cells to inform the diagnosis, prognosis, and monitoring of patients with immune-regulated conditions.
Featured Story: What is a Reverse Stock Split?
Receive News & Ratings for Oxford Immunotec Global Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Oxford Immunotec Global and related companies with MarketBeat.com's FREE daily email newsletter.